宣白承气汤联合氨溴索、血必净注射液治疗重症肺炎合并急性呼吸窘迫综合征临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563.1;R563.8

基金项目:


Clinical Study on Xuanbai Chengqi Tang Combined with Ambroxol and Xuebijing Injection for Severe Pneumonia Complicated with Acute Respiratory Distress Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察宣白承气汤联合氨溴索、血必净注射液治疗重症肺炎合并急性呼吸窘迫综合征的临床疗效及对患者血清相关因子的影响。方法:将60 例重症肺炎合并急性呼吸窘迫综合征患者作为研究对象,按随机数字表法分为研究组与对照组各30 例。对照组接受氨溴索联合血必净注射液治疗,研究组在对照组基础上增加宣白承气汤治疗。比较2 组临床疗效及治疗前后中医证候积分、降钙素原(PCT)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)、第1 秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰值流速(PEF)、血氧饱和度(SaO2)、血氧分压(PaO2)、氧合指数(PaO2/FiO2)。结果:研究组治疗总有效率为93.33%,高于对照组的73.33% (P<0.05)。与同组治疗前比较,治疗后2 组中医证候积分、PCT、IL-6、CRP 水平均降低(P<0.05),FEV1、FVC、PEF、SaO2、PaO2、PaO2/FiO2 均升高(P<0.05);与对照组治疗后比较,研究组治疗后中医证候积分、PCT、IL-6、CRP 水平均较低(P<0.05),FEV1、FVC、PEF、SaO2、PaO2、PaO2/FiO2 均较高(P<0.05)。研究组治疗过程中不良反应发生率23.33%,低于对照组43.33%(P<0.05)。结论:宣白承气汤联合氨溴索、血必净注射液能够有效治疗重症肺炎合并急性呼吸窘迫综合征患者,改善患者肺功能及呼吸状况,降低炎症反应与不良反应产生的风险,有良好的治疗效果且安全性较高。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Xuanbai Chengqi tang combined with ambroxol and Xuebijing injection for severe pneumonia complicated with acute respiratory distress syndrome and its effect on serum related factors. Methods:A total of 60 cases of patients with severe pneumonia complicated with acute respiratory distress syndrome were selected as the study subjects and divided into the study group and the control group according to the random number table method,with 30 cases in each group. The control group was treated with ambroxol combined with Xuebijing injection,and the study group was additionally treated with Xuanbai Chengqi tang based on the treatment of the control group. The Chinese medicine syndrome scores,procalcitonin(PCT),interleukin-6(IL-6),C-reactive protein(CRP),forced expiratory volumes in one second(FEV1),forced vital capacities(FVC),peak expiratory flows(PEF),oxygen saturations(SaO2),partial pressures of blood oxygen(PaO2) and oxygenation values(PaO2/FiO2) before and after treatment as well as the clinical effects in the two groups were compared. Results:The total effective rate was 93.33% in the study group,higher than that of 73.33% in the control group(P<0.05). After treatment, the Chinese medicine syndrome scores, PCT, IL- 6 and CRP levels in the two groups were decreased when compared with those before treatment(P<0.05),and FEV1,FVC,PEF,SaO2,PaO2 and PaO2/ FiO2 were increased(P<0.05);the Chinese medicine syndrome score,PCT,IL-6 and CRP levels in the study group were lower than those in the control group(P<0.05),and FEV1,FVC,PEF,SaO2,PaO2 and PaO2/FiO2 were higher(P<0.05). The incidence of adverse reactions was 23.33% in the study group, lower than that of 43.33% in the control group(P<0.05). Conclusion:Xuanbai Chengqi tang combined with ambroxol and Xuebijing injection can effectively treat patients with severe pneumonia complicated with acute respiratory distress syndrome, improve their lung function and respiratory status, and reduce the risk of inflammatory responses and adverse reactions,with a good curative effect and high safety.

    参考文献
    相似文献
    引证文献
引用本文

娄利梅,孙岚英,张群成.宣白承气汤联合氨溴索、血必净注射液治疗重症肺炎合并急性呼吸窘迫综合征临床研究[J].新中医,2021,53(21):35-39

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-11-12
  • 出版日期:
文章二维码